The following statement was issued by Black Workers for Justice, based in North Carolina.Again, we see the U.S. government trying to start another war as a diversion from the capitalist crisis that is causing great suffering among masses of working-class and poor people. The U.S. wars violate international laws and the U.S. Constitution, while attacking basic democratic and human rights to challenge the suffering and brutality carried out by the capitalist economy and the “State” (government).Trump got elected president on the racist promise of making America great again! Trump is intensifying the War on Black America — killing, maiming and jailing Black and Brown people, criminalizing immigrants and Muslims, and fostering regime change throughout the Americas.This attack on Syria is part of a U.S.-led global war that includes the War on Black America. Black people must oppose this war on Syria, all wars abroad and in the U.S. This war contributes to the economic and social crises.As our tax money is spent by the ruling 1% for war, there are more cuts to public services, schools, vocational education, jobs, health care, affordable housing, clearing up the environment, repairing the infrastructure, and supporting veterans that are disabled and mentally broken from fighting in these imperialist wars.The struggle for Black liberation must also be a struggle against imperialist wars. The European heads of the global capitalist system — the U.S., France and the U.K. are again deciding what part of the world they want to dominate and control for increasing their wealth, and positioning their militaries to dominate the world.We Say No to U.S. Led Racist and Imperialist Wars!FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Previous articleHoroscope: August 25, 2017Next articleStudent reported incident being investigated by Fort Worth police as sexual assault Branson Nelson RELATED ARTICLESMORE FROM AUTHOR ReddIt Iqbal leads women’s golf to fourth-place finish at Big 12 Tournament Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ TCU rowing program strengthens after facing COVID-19 setbacks A COVID-19 Charles Schwab Challenge Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Linkedin Women’s golf heads to Oklahoma for chance at first Big 12 title Photo courtesy of gofrogs.com Twitter Twitter + posts ReddIt Branson Nelson printAdrien Mörk is a new assistant coach of the men’s golf team.Mörk joins the staff after serving as an assistant coach at the University of Central Florida (UCF) for two years. Prior to his stint at UCF, Mörk coached for the French Golf Federation and served as the French Team Advisor at the 2015 European Team Championship in Sweden. He also coaches LPGA professional Perrine Delacour.“I’ve known the TCU program ever since Julien Brun played there,” Mörk said. “I know how good the program under Coach Montigel has been, so I couldn’t believe it when I got the phone call about the job. TCU is one of the top programs in the nation, and I feel like we can do something special in the next few years.”After winning the French High School Championship, Mörk played collegiately at McNeese State University from 2001-2004. He was a four-year team MVP and member of the All-Southland Conference team. He was the Louisiana Freshman of the Year in 2001 and advanced to the NCAA Regionals as an individual twice.As a professional, Mörk was the first player to shoot a 59 on the European Tour, an accomplishment he achieved in the second round at the 2006 Morocco Classic. The 59 followed an opening round of 63, giving him the lowest 36-hole score of any PGA Tour event at 122. In addition, Mörk won four times on the Alps Tour.“I’m really excited about the addition of Adrien Mörk to our golf program,” head coach Bill Montigel said. “He brings with him experience and success in recruiting, as well as national championship appearances. He is going to be a great fit for TCU and the guys will love him.”Mörk, his wife Sandrine and daughter Elin will be relocating to Fort Worth.“Everyone I know that lives in Fort Worth tells me how great it is,” Mörk said. “I can’t wait to be a part of the community and call Fort Worth and TCU home.” Facebook Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Equestrian earns last seed in NCEA team bracket Branson is a junior journalism major from Fort Worth, Texas. He enjoys writing about all sports and plans to go to law school after graduation. Facebook Another series win lands TCU Baseball in the top 5, earns Sikes conference award Linkedin TCU baseball finds their biggest fan just by saying hello
Home Local News Business DAILY OIL PRICE: April 16 Snap Inc. to Participate in the Morgan Stanley Technology, Media & Telecom Conference 2021 Congressman Mike Conaway talks to the Odessa American on Jan. 7, 2018. Previous articleCouple charged with sexually abusing childNext articleHighway 285 traffic pattern to change admin RELATED ARTICLESMORE FROM AUTHOR Pinterest Rattler Midstream: 4Q Earnings Snapshot WhatsApp By admin – April 16, 2018 Crude Oil: 66.22 (-1.17)Nymex MTD AVG: 64.7350.Natural Gas: 2.752 (+.017).Gasoline: 2.0399 (-0.0255).Spreads: May/June (-.02) June/July (+.26).Plains WTI Posting: 63.00 (-.75). Twitter Octopus Energy U.S. to Discount Customers’ Bills by as Much as 90% Local NewsBusiness DAILY OIL PRICE: April 16 WhatsApp Facebook Foolproof Roasted Pork TenderloinVirgin Coco MojitoSlap Your Mama It’s So Delicious Southern Squash CasserolePowered By 10 Sec Mama’s Deviled Eggs NextStay Pinterest Facebook Twitter
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory (R/R) hematologic malignancies. “In dosing the first patient in this Phase 1 study evaluating CA-4948 and ibrutinib, we are taking a highly anticipated step forward in bringing a potent oral therapeutic regimen to patients with relapsed or refractory hematologic malignancies,” said James Dentzer, President and Chief Executive Officer of Curis. “BTK inhibitors are an approved category of therapies for patients with various lymphatic cancers yet they only target one of the two main pathways activating NF-κB in B-cell malignancies. CA-4948 targets the other main NF-κB-activating pathway by shutting down signaling through the Myddosome. We have shown highly encouraging increased tumor-reducing activity when combining both covalent and non-covalent BTK inhibitors with CA-4948 in preclinical models.” Mr. Dentzer continued, “We observed single-agent activity in the non-Hodgkin’s lymphoma (NHL) monotherapy study, with the majority of patients treated at 300mg twice daily experiencing at least some reduction in tumor volume. We coordinated with our trial partners to amend the protocol of our existing study to include combination therapy starting at a previously demonstrated therapeutic dose. This will allow us to leverage the clinical sites and staff currently active in our monotherapy study and should save significant time and resources as we advance through the clinic.” “Given the profile CA-4948 has demonstrated in existing studies, it is a promising candidate for combination with a proven BTK inhibitor such as ibrutinib,” said Dr. Erel Joffe, M.D., Assistant Attending with the Lymphoma Service at Memorial Sloan Ketting Cancer Center and a lead investigator on the study. “We believe there may be important synergies given that IRAK4 controls the critical TLR pathway that is parallel and complementary to the BTK pathway and that both of these pathways are primary and independent oncogenic activators of NF-κB in lymphoma and leukemia. Effective dual targeting of both independent pathways that drive excessive B-cell proliferation via NF-κB could potentially provide significantly improved outcomes over either treatment in a monotherapy setting.” About the CA-4948+ibrutinib Phase 1 Combination Study The Phase 1 trial is a two-part, multicenter, open-label, dose escalation and expansion study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, clinical activity, and biomarker correlations of CA-4948 and ibrutinib patients with relapsed or refractory hematologic malignancies. Part 1 of the study is a dose escalation using a 3+3 design. Approximately 18 patients will be enrolled in Part 1 and will receive a starting dose of 200mg CA-4948 BID with subsequent escalation to 300mg BID, both of which have been observed to be safe and effective in the NHL monotherapy study, combined with ibrutinib doses appropriate for their respective NHL subtype. The primary endpoints of Part 1 will be safety and tolerability, maximum tolerated dose, and the recommended Phase 2 dose. Secondary objectives will be pharmacokinetics and preliminary efficacy. Exploratory objectives will include biomarker correlations, such as MYD88-L265P mutations and IRAK4 pathway and NFκB inhibition. Part 2 of the study will enroll patients across an expansion basket of four cohorts: marginal zone lymphoma (MZL), ABC-DLBCL, primary central nervous system lymphoma (PCNSL), and NHL with adaptive ibrutinib resistance. An interim futility analysis will be conducted after approximately 15-20 patients are enrolled in each cohort. Primary endpoints of Part 2 will be complete response or objective response rate and duration of response compared to historical controls. Secondary objectives will be safety and tolerability, progression-free survival, and population PK sampling for CA-4948. Exploratory objectives will include response correlation with biomarkers including MYD88-L265P or other genetic mutations, gene expressions, cell of origin, IRAK4 signaling, and resistance. About Curis, Inc. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin’s lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding any expectations of the potential for the Company’s proprietary drug candidate CA-4948, including the potential developments and benefits of CA-4948 in combination with BTK inhibitors such as ibrutinib, statements with respect to the timing of the Company’s studies, including enrollment and reporting of data, and the Company’s ability to advance and broaden its clinical programs. Forward-looking statements may contain the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “seeks,” “estimates,” “assumes,” “will,” “may,” “could” or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis’s drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis’s drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreements with Aurigene and ImmuNext will continue for their full terms, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech’s and/or Roche’s ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate some of its research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, any of its product candidates, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis also faces risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis’s control could significantly disrupt its operations or the operations of third parties on which Curis depends, and could adversely impact Curis’s operating results and its ability to raise capital. For example, the COVID-19 pandemic may result in closures of third-party facilities, impact enrollment in clinical trials or impact sales of Erivedge by Genentech and/or Roche. The extent to which the COVID-19 pandemic may impact Curis’s business or operating results is uncertain. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the caption “Risk Factors” in our most recent Form 10-K and Form 10-Q and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission (“SEC”). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis’s views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law. View original content to download multimedia: http://www.prnewswire.com/news-releases/curis-doses-first-patient-in-phase-1-study-of-ca-4948-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-hematologic-malignancies-301224625.html SOURCE Curis, Inc. Local NewsBusiness WhatsApp Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies Facebook Pinterest Pinterest By Digital AIM Web Support – February 9, 2021 TAGS Twitter Twitter WhatsApp Facebook Previous articleDaniel Kagan Promoted to President at Scientist.comNext articleArtisanal Self-Care Subscription Box Brand Little Slacks Announces Valentine’s Day Giveaway Digital AIM Web Support
Twitter Secretive Israeli nuclear facility undergoes major project Facebook Twitter WhatsApp Pinterest WhatsApp TAGS Local NewsWorld News By Digital AIM Web Support – February 25, 2021 Facebook Pinterest Previous articleADVA berichtet Rekordergebnis für Q4 2020 und veröffentlicht Gesamtjahreszahlen 2020Next articlePetersen helps Kings beat Blues 2-1 for 6th straight win Digital AIM Web Support
iStock/Thinkstock(NEW YORK) — Jeffrey Epstein, the disgraced millionaire who was facing federal sex trafficking charges, died by suicide early Saturday in his Lower Manhattan prison cell, three law enforcement officials told ABC News. Epstein hanged himself, law enforcement sources said. He was transported in cardiac arrest at 6:39 a.m. from Metropolitan Correctional Center to New York Downtown Hospital, according to sources.Epstein, 66, was set to stand trial next year for allegedly sexually abusing dozens of minor girls in New York and Florida.His death came less than three weeks after he was found unresponsive in his cell at the federal prison in Lower Manhattan, with marks on his neck that appeared to be self-inflicted, sources told ABC News.He had been on suicide watch since the July 23 incident.Epstein was arrested in July of this year for alleged sex trafficking of minor girls at his Upper East Side mansion and his home in Palm Beach, Florida. Some of the charges date back to the early 2000s.Epstein, 66, pleaded not guilty to the charges. He faced up to 45 years in prison if convicted.His alleged crimes were thrown back into the spotlight amid renewed scrutiny of the plea deal Epstein reached with the U.S. Attorney’s Office in Miami in 2007, led by then-U.S. Attorney Alexander Acosta. A non-prosecution agreement allowed Epstein, a hedge-fund manager, to plead guilty to two state charges and avoid federal charges for an allegedly broad pattern of similar sexual misconduct. He would serve just 13 months of an 18-month sentence in county jail in Florida.The alleged victims in that case told ABC News they were not made aware of the details of the plea agreement while it was being negotiated.The deal is currently under review by the Justice Department’s Office of Professional Responsibility. Acosta was serving as President Trump’s Labor Secretary amid the controversy over his role in the deal. He later resigned from that position.On Friday, a federal appellate court in New York unsealed around 2,000 pages of documents from a now-settled civil defamation case between Virginia Roberts Giuffre, an alleged Epstein victim, and British socialite Ghislaine Maxwell, a longtime Epstein associate.Giuffre accused Maxwell of recruiting her while she was working as a locker-room attendant at Mar-A-Lago in 2000 and bringing her to Epstein’s home for a massage. She claims that she eventually became a teen sex slave to Epstein, and a victim of sex trafficking, beginning at age 17, at the hands of both Epstein and Maxwell.The newly-unsealed documents showed that Giuffre alleged that Epstein and Maxwell directed her to have sex with, among others: Prince Andrew; criminal defense attorney Alan Dershowitz; former New Mexico governor Bill Richardson; former Senator George Mitchell; a well-known prime minster, who she wouldn’t name; and a foreign man who was introduced to her as a “prince.”Maxwell has consistently denied Giuffre’s claims.“Ghislaine Maxwell did not participate in, facilitate, manage or otherwise conspire to commit sex trafficking” as alleged by Giuffre, her attorney wrote in a 2016 court filing.Maxwell’s attorneys also contend in the newly unsealed court filings that Giuffre had “utterly failed” to substantiate her allegations that Maxwell facilitated her abuse. Giuffre’s claims about having been trafficked to other prominent men, Maxwell’s lawyers wrote, are “patently incredible.”Mitchell called the allegations “false.”“I have never met, spoken with or had any contact with Ms. Giuffre,” he said in a statement issued Friday. “In my contacts with Mr. Epstein I never observed or suspected any inappropriate conduct with underage girls. I only learned of his actions when they were reported in the media related to his prosecution in Florida. We have had no further contact.”Richardson also denied Giuffre’s claims.“These allegations and inferences are completely false. Governor Richardson has never even been contacted by any party regarding this lawsuit,” Maddy Mahony, a spokeswoman for Richardson, said in a statement. “To be clear, in Governor Richardson’s limited interactions with Mr. Epstein, he never saw him in the presence of young or underage girls. Governor Richardson has never been to Mr. Epstein’s residence in the Virgin Islands. Governor Richardson has never met Ms. Giuffre.”Giuffre’s allegations were never tested in court because the case was settled prior to trial.During a detention hearing in July, Epstein came face-to-face with two other accusers. Annie Farmer said she was 16 when Epstein had her sent to New Mexico where he was allegedly “inappropriate” with her. Courtney Wild told the judge she was 14 when Epstein allegedly sexually abused her in Palm Beach, Florida. Both women spoke in support of keeping Epstein locked up without bail.Epstein appeared to watch them address the judge, but his face showed no emotion.A federal judge later denied bail for Epstein, after deciding he was too great a flight risk to release from custody.Copyright © 2019, ABC Radio. All rights reserved.
Written by March 6, 2018 /Sports News – National Tom Brady: Patriots’ Super Bowl loss was ‘a great lesson’ for my children FacebookTwitterLinkedInEmailABC News(NEW YORK) — Tom Brady, after reflecting on the New England Patriots’ Super Bowl loss to the Philadelphia Eagles, says the defeat was an opportunity to teach his kids a valuable lesson.Brady’s three children — Vivian, 5, John, 10, and Benjamin, 8, — were visibly upset after watching his team lose.“That was the first time that I’d seen my kids really react in that way,” Brady, 40, said on his Facebook show Tom vs. Time.“You know, Benny was crying, Vivi was crying and they were sad for me and sad for the Patriots. But I just said to them, ‘Look you guys this is a great lesson. We don’t always win. We try our best and sometimes it doesn’t go the way we want.’”Copyright © 2018, ABC Radio. All rights reserved. Beau Lund
Email* Subscribe to the Horse Sport newsletter and get an exclusive bonus digital edition! Horse Sport Enews The FEI has imposed a further two-week extension of the shutdown of all international events in mainland Europe until 11 April 2021 due to the ongoing outbreak of the neurological form of Equine Herpes Virus (EHV-1). The FEI had previously announced a 28-day shutdown on 1 March 2021.The move, which aims to minimise the further spread of the very aggressive strain of the virus, was unanimously approved at an emergency FEI Executive Board meeting today. The extended lockdown applies to all FEI disciplines.The decision is based on detailed scientific risk assessment conducted by world leading epidemiologist Dr Richard Newton and the FEI Veterinary Department.The extended lockdown applies to all countries that have international scheduled events in the period to 11 April – Austria, Belgium, Spain, Estonia, France, Germany, Italy, Netherlands, Poland, Portugal and Sweden. However, the FEI again strongly recommends that all National Federations in mainland Europe cancel their national events in order to minimise horse movement.The shutdown will mean the cancellation of the FEI World Cup™ Finals for the second consecutive year following the loss of the 2020 Finals in Las Vegas (USA) to the Covid-19 pandemic.The Longines FEI Jumping World Cup™ Final and the FEI Dressage World Cup™ Final were scheduled to be held in Gothenburg (SWE) from 31 March to 4 April 2021.“The extension of the lockdown is difficult for everyone, and the loss of the FEI World Cup Finals for a second year is particularly devastating, especially for the qualified athletes and for our loyal Top Partner Longines,” FEI Secretary General Sabrina Ibáñez said. “We know how much work Tomas Torgersen and his incredible team in Gothenburg have put into organising the 2021 Finals, which would have been part of the 400th birthday anniversary celebrations for the city, so this is a desperately bitter blow.“We cannot eradicate EHV as it is endemic in many countries, but we need to work together to minimise the transmission of this particular strain, which has already caused the death of 12 horses in Europe. All of the original in-contact horses from Valencia, Vejer de la Frontera and Doha are already blocked on the FEI Database, but the whole community needs to be on the alert and monitoring their horses. We strongly urge all European-based FEI athletes to avoid travel with their horses during this prolonged shutdown, as travel is a very clear risk factor.“Sadly this additional lockdown is crucial to slow down the spread of the virus so that we can preserve the rest of the season, get our athletes and horses back competing safely and allow as long a period as possible for those aiming for Tokyo to earn their Minimum Eligibility Requirements and confirmation results, and of course to prepare their horses for the Games.“Nobody wants to see an outbreak like this ever again. There will be a comprehensive and fully transparent investigation into every aspect of this outbreak and the way it has been handled, and the findings will be published so that, together with our community, we can all learn from this.“We will be putting in place enhanced protocols to allow for a safe return to play once this outbreak is under control, and we will advise our community on those well in advance of the resumption of international events, but the priority right now has to be the treatment of sick horses and getting healthy horses back to their home countries in a safe and biosecure way. We all need to focus on safeguarding not just FEI horses, but the wider European horse community.”Work on identifying the gene sequencing of this strain of the virus is already underway, and the FEI is continuing to monitor the evolution of the virus through the FEI Veterinary Epidemiology Working Group, which was formalised this week. The Group is composed of world-leading EHV specialists, the FEI Veterinary Director and FEI Senior Veterinary Advisor, supported by the Chair of the FEI Veterinary Committee. Reports and recommendations from this Group will be published on a weekly basis.The FEI is also publishing daily updates on the dedicated EHV-1 hub. We’ll send you our regular newsletter and include you in our monthly giveaways. PLUS, you’ll receive our exclusive Rider Fitness digital edition with 15 exercises for more effective riding. Tags: Dressage, EHV-1, show jumping, Gothenburg, World Cup™ Final, More from News:MARS Bromont CCI Announces Requirements For US-Based RidersThe first set of requirements to allow American athletes and support teams to enter Canada for the June 2-6 competition have been released.Canadian Eventer Jessica Phoenix Reaches the 100 CCI4*-S MarkPhoenix achieved the milestone while riding Pavarotti at the inaugural 2021 CCI4*-S at the Land Rover Kentucky Three-Day Event.Tribunal Satisfied That Kocher Made Prolonged Use of Electric SpursAs well as horse abuse, the US rider is found to have brought the sport into disrepute and committed criminal acts under Swiss law.Washington International Horse Show Returns to TryonTIEC will again provide the venue for the WIHS Oct. 26-31 with a full schedule of hunter, jumper and equitation classes. SIGN UP
Back to overview,Home naval-today Austal USA Bags LCS Services Deal View post tag: deal View post tag: services Authorities Austal USA Bags LCS Services Deal View post tag: Bags View post tag: Navy View post tag: americas View post tag: News by topic View post tag: LCS Share this article View post tag: Naval View post tag: Austal USA October 15, 2014 The United States Department of Defense has announced that Austal USA has been awarded a US$8.440 million cost-plus contract modification to a previously awarded Littoral Combat Ship (LCS) contract.The contract exercises options for core class services for the LCS Program.Austal USA will assess engineering and production challenges, as well as develop, evaluate costs and schedule risks for engineering change proposals and class baseline documentation in support of production efforts.Work will be performed in Mobile, Alabama (60 percent), and Pittsfield, Massachusetts (40 percent), and work is expected to be completed October 2015.The Naval Sea Systems Command, Washington, D.C., is the contracting activity.[mappress]Image: Austal
Christ Church have beaten Sheffield in the University Challenge final, which was aired on BBC2 last night. The final score was 220 points to 170. Over 200 teams from around the country entered this year’s competition, but only 28 were selected to compete in the televised stages. This is the 14th time an Oxford college has won since the programme began in 1963, compared with 6 wins for Cambridge.